Loading
Life sciences · Journal article
Biomedicines · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pulmonary fibrosis is a frequent complication of abnormal tissue repair following lung injury by many causes. It can be found in various diseases and clinical conditions, such as idiopathic pulmonary fibrosis, cancer-treatment-induced lung injury, and other occupational, environmental, and autoimmune lung diseases. Though the initiating factors of these conditions are different, they have several biological mechanisms in common during disease progression, such as injury to and abnormal repair of alveolar epithelial and vascular endothelial cells, immune microenvironment remodeling, macrophage reprogramming, persistent activation of fibroblasts, excessive extracellular matrix deposition, and mechanically driven positive feedback loops. Recent single-cell and spatial multi-omics developments have changed the direction of pulmonary fibrosis research to concentrate on individual signaling pathways to obtain a wider perspective of interactions between cell types. These investigations have discovered significant cell populations, such as abnormal basal-like epithelial cells, SPP1+/TREM2+ profibrotic macrophages, and CTHRC1+ pathological fibroblasts. They have also uncovered new processes, including metabolic–epigenetic interactions, endothelial-to-mesenchymal transition, and macrophage-to-myofibroblast transition that give a new understanding to the pathogenesis of diseases. Pirfenidone and nintedanib may slow the progression of lung dysfunction but do not reverse already existing fibrosis. Thus, knowledge of the complicated cellular and molecular processes of pulmonary fibrosis is critical in determining new therapeutic targets and enhancing existing therapies. This review summarizes pathological characteristics, mechanisms and therapeutic breakthroughs with special emphasis on idiopathic pulmonary fibrosis and cancer-therapy-related lung damage and discusses emerging strategies targeting epithelial repair, endothelial barrier activity, macrophage activity, fibroblast activation, and extracellular matrix remodeling.